<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140450</url>
  </required_header>
  <id_info>
    <org_study_id>910292</org_study_id>
    <nct_id>NCT02140450</nct_id>
  </id_info>
  <brief_title>Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection</brief_title>
  <official_title>Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular
      pressure rise after intravitreal injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute intraocular pressure elevation after intravitreal injection of bevacizumab was
      proven.Acute intraocular pressure elevation most probably is volume related and long term
      intraocular pressure elevation relates to pharmacologic features of the medications which
      results in anatomic changes in the angle of anterior chamber.Numerous studies found an
      intraocular pressure elevation right after the injection and quick normalization within
      maximally 30 minutes.This intraocular pressure elevation which lasts about 30 minutes, can
      result in irreversible visual loss especially in patients with critical remaining nerve
      fibers in the optic nerve head, as occurs in glaucomatous patients. Is there any way to
      prevent or even shorten this time of intraocular pressure elevation? We tried in our study to
      find a suitable response for a question above, so we used several anti-glaucoma agents
      (Timolol, Brimonidine, Acetazolamide, Mannitol versus placebo) as a prophylaxis to prevent
      acute intraocular pressure elevation right after intravitreal bevacizumab injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in IOP</measure>
    <time_frame>0, 5, 10, 15, 30 minutes after injection</time_frame>
    <description>the change in intraocular pressure after intravitreal injection of bevacizumab</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Intraocular Pressure Change in Intravitreal Injection</condition>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mannitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Artificial tears, 2 drops, 1-2 hours before intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection</description>
    <arm_group_label>Timolol</arm_group_label>
    <other_name>Timoptic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine</intervention_name>
    <description>Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection</description>
    <arm_group_label>Brimonidine</arm_group_label>
    <other_name>Alphagan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection</description>
    <arm_group_label>Mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Artificial tears, 2 drops, 1-2 hours before intravitreal injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients who candidate for receiving intravitreal bevacizumab

        Exclusion Criteria:

          -  patients who had advanced glaucoma

          -  patients who received antiglaucoma agents in the past

          -  patients who had corneal scar which affect IOP measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasser Shoeibi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Research Center, Khatam eye Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Khorasan Razavi</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Nasser Shoeibi</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>intraocular pressure, intravitreal injection, short term</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

